top of page
Search
All Posts
StiRx Showcases Advances in Next-Generation Immunotherapeutics at ISV Congress 2025
Boston, MA – October 2025  — StiRx, a biotechnology company pioneering next-generation biologics for sexually transmitted infections...
StiRx and International Vaccine Institute (IVI) Sign Memorandum of Understanding to Advance Monoclonal Antibody Technologies Against Drug-Resistant Gonorrhea
Boston, MA, August 2025 - StiRx Inc., a biotechnology company pioneering best-in-class vaccines and biologics against sexually...
StiRx Co-Founders Author Critical Review on Biologic Therapies for Sexually Transmitted Infections
Boston, MA, May 2025  — Clinical Microbiology Reviews  has published a critical review article authored by StiRx Co-Founders Davinder...
StiRx Inc. to Present Breakthrough Research on Gonorrhea Therapeutics at IPNC 2025
Boston, MA, April 2025  – StiRx Inc., a biotechnology company focused on advancing sexual health through innovative biologics, is proud...
bottom of page